BACKGROUND: Bronchoscopic coil treatment has been shown to improve pulmonary function, exercise capacity, and quality of life in patients with severe emphysema. OBJECTIVES: To perform a meta-analysis of the results of four independent European clinical trials investigating this coil therapy for emphysema. METHODS: Data on all patients included in the four European clinical trials were analyzed for efficacy and safety outcomes. RESULTS: A total of 2,536 coils were placed during 259 procedures in 140 patients. A total of 37 chronic obstructive pulmonary disease exacerbations and 27 pneumonias were recorded as serious adverse events up to 1 year after treatment. The pneumothorax rate was 6.4%. Both 6 and 12 months after treatment, significant (all p < 0.001) improvements were observed for: forced expiratory volume in 1 s [+0.08 liters (±0.19) and +0.08 liters (±0.21)], residual volume [RV; -510 ml (±850) and -430 ml (±720)], 6-min walking distance [6MWD; +44.1 m (±69.8) and +38.1 m (±71.9)], and St. George's Respiratory Questionnaire score [SGRQ; -9.5 points (±14.3) and -7.7 points (±14.2)]. No differences in any outcome measures were observed between heterogeneous and homogeneous emphysema patients. Only a high baseline RV was found to be an independent predictor of successful treatment. CONCLUSIONS: Bronchoscopic coil treatment improves pulmonary function, 6MWD, and quality of life in patients with severe emphysema up to 1 year after treatment, independent of the distribution of the disease.
BACKGROUND: Bronchoscopic coil treatment has been shown to improve pulmonary function, exercise capacity, and quality of life in patients with severe emphysema. OBJECTIVES: To perform a meta-analysis of the results of four independent European clinical trials investigating this coil therapy for emphysema. METHODS: Data on all patients included in the four European clinical trials were analyzed for efficacy and safety outcomes. RESULTS: A total of 2,536 coils were placed during 259 procedures in 140 patients. A total of 37 chronic obstructive pulmonary disease exacerbations and 27 pneumonias were recorded as serious adverse events up to 1 year after treatment. The pneumothorax rate was 6.4%. Both 6 and 12 months after treatment, significant (all p < 0.001) improvements were observed for: forced expiratory volume in 1 s [+0.08 liters (±0.19) and +0.08 liters (±0.21)], residual volume [RV; -510 ml (±850) and -430 ml (±720)], 6-min walking distance [6MWD; +44.1 m (±69.8) and +38.1 m (±71.9)], and St. George's Respiratory Questionnaire score [SGRQ; -9.5 points (±14.3) and -7.7 points (±14.2)]. No differences in any outcome measures were observed between heterogeneous and homogeneous emphysemapatients. Only a high baseline RV was found to be an independent predictor of successful treatment. CONCLUSIONS: Bronchoscopic coil treatment improves pulmonary function, 6MWD, and quality of life in patients with severe emphysema up to 1 year after treatment, independent of the distribution of the disease.
Authors: Felix J F Herth; Dirk-Jan Slebos; Pallav L Shah; Martin Hetzel; Gerald Schmid-Bindert; Adam S LaPrad; Gaëtan Deslée; Arschang Valipour Journal: Respiration Date: 2019-11-19 Impact factor: 3.580
Authors: Jorine E Hartman; Karin Klooster; Sonja W S Augustijn; Wouter H van Geffen; Justin L Garner; Pallav L Shah; Nick H T Ten Hacken; Dirk-Jan Slebos Journal: Respiration Date: 2021-03-19 Impact factor: 3.580
Authors: Juergen Hetzel; Michael Boeckeler; Marius Horger; Ahmed Ehab; Christopher Kloth; Robert Wagner; Lutz Freitag; Dirk-Jan Slebos; Richard Alexander Lewis; Maik Haentschel Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-08-30
Authors: Christian Doppler; Kathrin Arnhard; Julia Dumfarth; Katharina Heinz; Barbara Messner; Christian Stern; Therese Koal; Kristaps Klavins; Katarina Danzl; Florian Pitterl; Michael Grimm; Herbert Oberacher; David Bernhard Journal: PLoS One Date: 2017-05-03 Impact factor: 3.240